- Home
- SLRX vs PTIX Comparison
SLRX vs PTIX Comparison
Compare SLRX & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- PTIX
- Stock Information
- Founded
- SLRX N/A
- PTIX 1994
- Country
- SLRX United States
- PTIX United States
- Employees
- SLRX N/A
- PTIX N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- PTIX Health Care
- Exchange
- SLRX Nasdaq
- PTIX Nasdaq
- Market Cap
- SLRX 2.9M
- PTIX 2.7M
- IPO Year
- SLRX N/A
- PTIX 2016
- Fundamental
- Price
- SLRX $5.29
- PTIX $3.22
- Analyst Decision
- SLRX
- PTIX
- Analyst Count
- SLRX 0
- PTIX 0
- Target Price
- SLRX N/A
- PTIX N/A
- AVG Volume (30 Days)
- SLRX 129.8K
- PTIX 8.3M
- Earning Date
- SLRX 11-13-2025
- PTIX 09-10-2025
- Dividend Yield
- SLRX N/A
- PTIX N/A
- EPS Growth
- SLRX N/A
- PTIX N/A
- EPS
- SLRX N/A
- PTIX N/A
- Revenue
- SLRX N/A
- PTIX N/A
- Revenue This Year
- SLRX N/A
- PTIX N/A
- Revenue Next Year
- SLRX N/A
- PTIX N/A
- P/E Ratio
- SLRX N/A
- PTIX N/A
- Revenue Growth
- SLRX N/A
- PTIX N/A
- 52 Week Low
- SLRX $4.50
- PTIX $2.25
- 52 Week High
- SLRX $108.00
- PTIX $15.26
- Technical
- Relative Strength Index (RSI)
- SLRX 39.91
- PTIX 49.37
- Support Level
- SLRX $4.50
- PTIX $2.79
- Resistance Level
- SLRX $5.65
- PTIX $3.39
- Average True Range (ATR)
- SLRX 0.40
- PTIX 0.36
- MACD
- SLRX 0.18
- PTIX -0.04
- Stochastic Oscillator
- SLRX 44.38
- PTIX 19.58
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.